EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Austar Lifesciences's Enterprise Value is $62.4 Mil.
Austar Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $14.5 Mil. Therefore, Austar Lifesciences's EV-to-FCF for today is 4.31.
The historical rank and industry rank for Austar Lifesciences's EV-to-FCF or its related term are showing as below:
AULSF'
s EV-to-FCF Range Over the Past 10 Years
Min: -848.45 Med: -5.98 Max: 110.1
Current: 4.29
During the past 13 years, the highest EV-to-FCF of Austar Lifesciences was 110.10. The lowest was -848.45. And the median was -5.98.
AULSF's EV-to-FCF is ranked better than 94% of 417
companies
in the Medical Devices & Instruments industry
Industry Median: 23.4
vs AULSF: 4.29
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Austar Lifesciences's PE Ratio (TTM) for today is calculated as:
Austar Lifesciences's share price for today is $0.02.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Austar Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Austar Lifesciences EV-to-FCF Related Terms
Austar Lifesciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Austar Lifesciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Austar Lifesciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Austar Lifesciences EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Austar Lifesciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Austar Lifesciences's EV-to-FCF falls into.
Austar Lifesciences's current Enterprise Value is $62.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Austar Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $14.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Austar Lifesciences (AULSF) has a EV-to-FCF of 4.31 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Austar Lifesciences and its competitors. According to the industry distribution chart, Austar Lifesciences ranks #25 out of 417 companies in the Medical Devices & Instruments industry, placing it in the top 6%.
Is Austar Lifesciences' EV-to-FCF too high?
Austar Lifesciences' current EV-to-FCF is 4.31. The Medical Devices & Instruments industry median EV-to-FCF is 23.40. Austar Lifesciences' value of 4.31 is 81.6% below this industry median. Based on the distribution chart, Austar Lifesciences ranks #25 out of 417 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Austar Lifesciences has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does Austar Lifesciences' EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Austar Lifesciences ranks #25 out of 417 companies for EV-to-FCF. This places Austar Lifesciences in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 23.40. Austar Lifesciences' value of 4.31 is 81.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 23.40, based on 417 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Austar Lifesciences's current EV-to-FCF of 4.31 is 81.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Austar Lifesciences and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 23.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Austar Lifesciences's current EV-to-FCF is 4.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Austar Lifesciences stock overvalued right now?
Austar Lifesciences (AULSF) has a current EV-to-FCF of 4.31. The stock's GF Value™ is $0.03, compared to a current price of $0.02 — trading 33.3% below its estimated fair value. The current EV-to-FCF is 4.31 and 81.6% below the Medical Devices & Instruments industry median of 23.40. Austar Lifesciences' overall GF Score™ is 49/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Austar Lifesciences (AULSF), the current EV-to-FCF is 4.31 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Austar Lifesciences (AULSF) Overvalued in 2026?
Based on GuruFocus' analysis, Austar Lifesciences stock appears to be undervalued.
The current stock price of $0.02 is trading 33.3% below its estimated GF Value™ of $0.03.
Key valuation signals for AULSF:
EV-to-FCF: 4.31
GF Value™: $0.03 vs. price of $0.02 (33.3% below fair value)
Industry Position: 81.6% below the Medical Devices & Instruments median (#25 of 417)
No single metric tells the full story. See the AULSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Austar Lifesciences Ltd is an investment holding company, and its subsidiaries are principally engaged in providing integrated engineering solutions to pharmaceutical manufacturers and research institutes, as well as manufacturing and distribution of pharmaceutical equipment and consumables in the PRC. Its products include Clean Utility Equipment & Chemical Pharmaceutical Preparation System and others. It has three business segment groups: Integrated Process and Packaging Equipment & Systems (IPS), which generates maximum revenue and combines the original business segments of Liquid and Bioprocess System and Powder and Solid System; Consulting, Digitalization, and Construction; and Life Science Equipment and Consumables. The Group generates maximum revenue from Mainland China.
49GF Score
Get the complete analysis for AULSF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AULSF has been successfully added to your 
